Camsing Healthcare Limited: FY2026 Financial Analysis and Investor Insights

Camsing Healthcare Limited, a Singapore-listed company specializing in health foods and supplements through its subsidiary Nature’s Farm Pte Ltd, released its interim financial statements for the three months and full year ended 31 January 2026. The following article presents a comprehensive review of the company’s performance, financial position, and notable corporate events based solely on the disclosed financials.

Key Financial Metrics & Performance Table

Historical Performance Trends

• The Group has recorded net losses for multiple consecutive years, with FY2026 loss before tax at S\$910k, down from S\$2,302k in FY2025.
• Revenue and gross profit continue to decline YoY, primarily due to closure of retail outlets and weaker consumer sentiment.
• Cost control measures have been effective, leading to significant reductions in marketing, distribution, and administrative expenses.
• Finance costs fell substantially, mainly due to the absence of loan interest from Qiren Holdings Pte Ltd in FY2026.
• Net liabilities increased to S\$6,170k (FY2025: S\$5,260k), with cash balances dropping to S\$40k and borrowings rising to S\$3,245k.

Exceptional Earnings and Expenses

• No impairment losses were recorded in FY2026, compared to significant impairment charges in FY2025 (right-of-use assets: S\$1,097k; plant/equipment: S\$145k).
• Other income dropped significantly due to the absence of loan and interest waivers, which contributed S\$1,335k in FY2025.
• Payables written off contributed positively to other income in both periods.

Directors’ Pay and Related Party Transactions

• Key management compensation totaled S\$406k for FY2026 (FY2025: S\$530k). Directors received S\$95k (FY2025: S\$166k) in short-term employee benefits.
• Loans from major shareholders and controlling shareholders were a key source of funding, totaling S\$800k in FY2026.
• No general mandate for Interested Person Transactions was obtained; no IPTs exceeded S\$100,000 in aggregate value.

Corporate Actions & Fundraising

• No share buybacks, placements, or asset sales in the period.
• The company issued S\$2.5m in zero-coupon mandatory convertible bonds in July 2024, fully accounted as equity. These bonds are convertible into 50m shares at S\$0.05/share, but are currently antidilutive.
• No dividends were declared or recommended for FY2026 or FY2025.

Events Impacting Business and Outlook

• No known significant subsequent events or legal disputes.
• Retail outlet closures adversely impacted revenue but the company managed to redirect customers to remaining outlets and digital channels.
• The company is actively reorganizing its retail portfolio, focusing on online expansion and cost efficiency.
• Ongoing discussions with strategic partners may yield new revenue streams.
• Material uncertainty exists regarding going concern, mitigated by shareholder support, cost reductions, and e-commerce growth.

Chairman’s Statement and Tone

“With uncertain global economic conditions, the Company anticipates consumer sentiment may be adversely impacted in the coming quarters. Nonetheless, we remain focused on disciplined cost management while positioning the business to maintain modest and sustainable growth.
Based on our ongoing review of the core business, the Company has begun reorganizing the retail portfolio at the start of FY2026 by closing down loss-making outlets while expanding our presence online. This rationalisation of our retail footprint reflects our commitment to improving operational efficiency and redirecting resources towards more productive channels. It is worth highlighting that despite multiple retail closures, the Company managed to retain most of its customers via redirection to other outlets or digital channels. Our online channel has also demonstrated encouraging momentum, recording improved growth during the period. Taken together, these initiatives reflect our ongoing efforts to streamline operations and preserve margins, and we are cautiously optimistic that the Group’s performance will continue on a stable and improving trajectory in the periods ahead.
The Group is also currently in discussions with potential strategic partners to explore new revenue streams through building on its existing business. The Company will update shareholders via announcements released on the SGXNet in due course, if there are material updates.”

The tone is cautiously optimistic, recognizing headwinds while emphasizing operational improvements, cost discipline, and retention of customer base despite retail downsizing.

Conclusion & Investor Recommendations

Overall, Camsing Healthcare Limited’s financial performance remains weak, marked by continued net losses, declining revenue, and negative net asset value per share. However, substantial cost reductions and the absence of impairment charges have helped reduce losses. The company is reliant on shareholder loans and faces material going concern uncertainties, but is actively restructuring for operational efficiency and online growth.

• If you currently hold this stock: Stay cautious. Consider the risks associated with ongoing losses, low liquidity, and high borrowings. Monitor for signs of successful turnaround, strategic partnerships, and sustained online growth. Investors should be prepared for prolonged volatility and the possibility of further dilution if convertible bonds are exercised.
• If you are not holding this stock: Avoid initiating new positions until clear evidence emerges of a turnaround or sustainable profitability. The risk profile remains high due to persistent losses, negative equity, and uncertain outlook. Wait for more material improvements or strategic developments.

Disclaimer: This analysis is based solely on the company’s published financial report and is not investment advice. Investors should conduct their own research and consider their risk tolerance before making investment decisions.

View Camsing Hc Historical chart here